ADHD Medication and Brain Data: What a qEEG Can Tell You About Your Treatment

You've been taking your ADHD medication for weeks — maybe months. Your prescriber asks how it's going. You say "I think it's helping?" They adjust the dose. You try again. A few weeks later: "Maybe? I'm not sure." They switch you to something else. The cycle continues.

This is the reality of ADHD medication management for millions of people in the UK. Treatment decisions are based almost entirely on self-report and clinical observation. Your prescriber is skilled and experienced — but they're working without the one thing that could transform the conversation: objective data about what the medication is actually doing to your brain.

That's where a qEEG brain screening changes the picture entirely.

The problem with "how do you feel?"

Under NICE guidelines (NG87), ADHD medication should be monitored through regular clinical review — including assessment of symptom change, side effects, and functional impact. In practice, this usually means a 15–20 minute conversation where you try to summarise how your brain has been performing across dozens of different contexts over the past month.

The challenge is that self-report is inherently unreliable for ADHD medication assessment. People with ADHD have difficulty with self-monitoring by definition — it's one of the core executive function deficits the medication is supposed to address. The very condition being treated impairs the ability to accurately evaluate the treatment.

Common scenarios every prescriber recognises:

• The placebo effect — you feel better because you're doing something, not necessarily because the medication is working at a neurological level.
• Confounding variables — your focus improved this week, but was that the medication, the better sleep, the reduced work stress, or the extra coffee?
• Dosage uncertainty — you're on 30mg of methylphenidate but you're not sure if you'd be better on 36mg, 54mg, or a different medication entirely. Neither is your prescriber, without objective data.
• Side effects masking benefits — the medication makes you anxious or suppresses your appetite, so you rate the experience negatively, even though your attention metrics may have genuinely improved.
• Tolerance questions — you've been on the same dose for a year and it doesn't feel as effective. Has tolerance developed, or have external circumstances changed?

None of these are failures of clinical skill. They're limitations of subjective assessment for a neurological condition. And there's a straightforward way to supplement that assessment with objective brain data.

What happens to the ADHD brain on medication

To understand what a qEEG can show you about your medication, you first need to understand what stimulant medication does at the neurological level.

The two most commonly prescribed ADHD stimulants in the UK — methylphenidate (Ritalin, Concerta, Equasym, Medikinet) and lisdexamfetamine (Elvanse) — both increase dopamine and norepinephrine availability in the prefrontal cortex. This shifts brain activity towards the pattern associated with focused attention: reduced slow-wave theta, increased fast-wave beta, and improved cortical arousal in the frontal regions.

Research published in the Journal of the American Academy of Child & Adolescent Psychiatry examined EEG changes in children with ADHD who received methylphenidate versus placebo. The findings were striking: children who responded well to medication showed significantly increased frontal beta activity and decreased theta activity — their brainwave patterns moved measurably closer to neurotypical norms. Children who did not respond showed the opposite pattern — beta actually decreased in the frontal regions.

A separate study in the Psychiatry Investigation journal confirmed that methylphenidate's strongest effects on brain activity appeared during attentional tasks rather than at rest — increasing beta and decreasing theta specifically when the brain was engaged in sustained concentration. This is exactly the functional context where ADHD causes the most difficulty, and where medication response matters most.

In simple terms: when stimulant medication works, the theta/beta ratio normalises. The excess slow-wave activity that characterises the ADHD pattern at rest is reduced. The fast-wave activity associated with concentration increases. The brain shifts from its default under-aroused state towards the pattern needed for focused attention.

And this shift is measurable. It shows up in a qEEG recording. That means we can capture it, compare it to your unmedicated baseline, and give you — and your prescriber — objective evidence of what the medication is doing at a neurological level.

Why medication response varies: the brain isn't one-size-fits-all

If ADHD medication worked the same way for everyone, prescribing would be simple. In reality, approximately 20–30% of people do not respond adequately to the first stimulant they try, and some don't respond to stimulants at all. The question is: why?

The largest brain imaging study of ADHD medication response — the international iSPOT-A study involving 336 children and adolescents — was published in European Neuropsychopharmacology and revealed a remarkable finding. No overall difference in brain activity was found between participants with and without ADHD. However, a clear difference was found between adolescents who did and did not respond to methylphenidate treatment.

The key biomarker was alpha peak frequency (APF) — a measure of the dominant speed of the brain's alpha oscillations. Adolescent males with a slower APF were significantly more likely to be medication non-responders. This suggests that the brain's individual neurophysiological profile determines treatment response — not just the diagnosis itself.

The study's lead author stated that brain imaging is more useful for prognosis (predicting treatment response) than for diagnosis — a distinction that directly supports the value of qEEG screening alongside medication management. Your brain's specific electrical profile influences which medication is likely to work, at what dose, and whether alternative approaches may be more appropriate.

The research also demonstrated clear sex differences in brain activity patterns, with EEG biomarkers predicting stimulant response in males but not females. This finding underscores the complexity of ADHD neurobiology and the need for personalised, data-driven treatment approaches rather than trial-and-error prescribing. For women and girls with ADHD, our guide to ADHD in women covers the specific challenges of diagnosis and treatment in female presentations.

How a medication comparison scan works

Our medication comparison scan is designed to capture your brain's activity in both states — unmedicated and medicated — in a single appointment. Here's exactly what happens:

Before the appointment

You attend without taking your morning stimulant dose. If you normally take methylphenidate, lisdexamfetamine, or dexamfetamine, skip that morning's dose only — with your prescriber's knowledge. If you're on a non-stimulant like atomoxetine or guanfacine, take it as normal (these medications work through different mechanisms and don't produce the same acute brainwave changes).

First recording: unmedicated baseline

We place the lightweight BrainBit headband and capture a full qEEG recording — 2 minutes eyes open, 2 minutes eyes closed, and the 3-minute Go/No-Go attention task. This is your unmedicated baseline — what your brain does without pharmaceutical intervention. The same recording protocol is described in detail on our how it works page.

Medication interval

You then take your normal medication dose. We wait for it to take effect — typically 30–60 minutes for immediate-release methylphenidate, 60–90 minutes for extended-release formulations, and 90–120 minutes for lisdexamfetamine. During this interval, you can relax, read, have a drink — there's no need to stay still or avoid activity.

Second recording: medicated state

Once the medication has reached therapeutic effect, we repeat the identical recording — eyes open, eyes closed, Go/No-Go task. Same headband, same protocol, same conditions. The only variable that has changed is the medication.

Comparison and report

The two datasets are analysed and compared. Your report shows the theta/beta ratio in both states, attention task performance in both states, and the delta (change) between them. Did theta decrease? Did beta increase? Did your attention task accuracy improve? Did your reaction time variability reduce? The answers are in the data — not in self-report.

You receive both recordings and the comparison analysis as a professional PDF report on the same day, with z-scores against published normative databases and clinical interpretation. This report is designed to be presented to your prescriber at your next medication review.

What the data looks like in practice

To understand the practical value, consider three common scenarios we see in clinic:

Scenario 1: Clear positive response

Unmedicated theta/beta ratio: z-score 2.4 (significantly elevated). Go/No-Go miss rate: 18% (well above average). Medicated theta/beta ratio: z-score 0.8 (within normal range). Go/No-Go miss rate: 5% (normal). This is the ideal outcome — medication is producing a measurable normalisation of brain activity and attention performance. The data supports the current medication and dose. The patient can present this to their prescriber with confidence.

Scenario 2: Partial response

Unmedicated theta/beta ratio: z-score 2.1. Go/No-Go miss rate: 14%. Medicated theta/beta ratio: z-score 1.6 (improved but still elevated). Go/No-Go miss rate: 9% (improved but still above average). The medication is having a measurable effect — but it hasn't fully normalised the pattern. This data supports a conversation with the prescriber about dose adjustment: the medication is working, but there may be room for optimisation. Without brain data, this partial response might be dismissed as "it's fine" or "it's not working" — both inaccurate.

Scenario 3: Minimal neurological change

Unmedicated theta/beta ratio: z-score 1.8. Go/No-Go miss rate: 12%. Medicated theta/beta ratio: z-score 1.7. Go/No-Go miss rate: 11%. Minimal change despite subjective reports of feeling slightly better. This data suggests the medication may not be producing the expected neurological shift. It opens a conversation about whether the dose is adequate, whether this medication type suits this individual's brain profile, or whether the perceived improvement is primarily a placebo or behavioural effect. This is arguably the most valuable outcome — it prevents months or years of taking a medication that isn't achieving what it should.

Medication types and what to expect from the data

Different ADHD medications work through different mechanisms, and this affects what a qEEG comparison can reveal about each one.

Methylphenidate (Ritalin, Concerta, Equasym, Medikinet)

Methylphenidate is the most commonly prescribed ADHD medication in the UK and the most studied in qEEG research. It works by blocking the reuptake of dopamine and norepinephrine, increasing their availability in the prefrontal cortex. Research published in Translational Neuroscience compared the qEEG effects of methylphenidate and atomoxetine in children with ADHD, finding that both produced measurable changes in frontal and temporal brain activity — though through different pathways.

In our medication comparison scans, methylphenidate typically produces the clearest and most immediate brainwave changes. Immediate-release formulations (Ritalin, Medikinet) reach peak effect within 30–60 minutes, while extended-release formulations (Concerta, Equasym XL) take 60–90 minutes. The comparison window is timed accordingly. When methylphenidate is working effectively, we typically observe a significant reduction in resting theta, an increase in frontal beta during the attention task, and measurable improvements in Go/No-Go accuracy and reaction time consistency.

Lisdexamfetamine (Elvanse)

Lisdexamfetamine is a prodrug — it's inactive until your body converts it to dexamfetamine in the bloodstream. This gives it a slower onset (typically 90–120 minutes to peak effect) and a smoother, longer duration. Because of the slower onset, the medication interval during a comparison scan is longer than for methylphenidate. The expected neurological changes are similar — reduced theta, increased beta, improved attention metrics — but the magnitude and pattern may differ from methylphenidate because of the different pharmacological profile.

For patients who have tried both methylphenidate and lisdexamfetamine, comparing the qEEG data from each can reveal which medication produces a stronger neurological shift. This is objective information that your prescriber cannot obtain from self-report alone.

Atomoxetine (Strattera) and guanfacine (Intuniv)

Non-stimulant medications work through fundamentally different mechanisms. Atomoxetine is a selective norepinephrine reuptake inhibitor that takes 4–6 weeks to reach full therapeutic effect. Guanfacine is an alpha-2 adrenergic agonist. Neither produces the same acute brainwave changes that stimulants produce within hours, so a single-session before-and-after comparison is less informative for these medications.

However, a baseline qEEG taken before starting a non-stimulant, followed by a second recording after 8–12 weeks of treatment, can reveal whether chronic medication use has produced measurable changes in your resting brain activity over time. If you're on atomoxetine or guanfacine and want to assess response, get in touch and we'll advise on the best timing for your recordings.

Combined medication approaches

Many people with ADHD take a combination of medications — a stimulant alongside a non-stimulant, or a stimulant with an antidepressant or anti-anxiety medication. A qEEG comparison can still be valuable in these cases, but interpretation becomes more nuanced because multiple pharmacological effects are occurring simultaneously. Your report's clinical interpretation section will account for this context, and the data provides your prescriber with a neurological baseline that informs decisions about adjusting any component of a combined regime.

What the data doesn't tell you

Brain data is powerful — but it's not the whole picture, and responsible use requires understanding its boundaries.

A qEEG medication comparison does not diagnose ADHD. It does not tell you which medication to take — that remains a clinical decision for your prescriber. It does not replace the need for regular clinical review, behavioural observation, and self-report. And it does not capture the full pharmacological effect of medications that work through longer-term neurochemical mechanisms, such as atomoxetine or guanfacine, which may not produce acute brainwave changes in a single-session comparison.

What it does provide is an additional dimension of information — objective, neurological, measurable — that enhances the clinical conversation. It turns "I think it might be helping" into "my theta/beta ratio dropped from 2.4 to 0.8 and my attention task accuracy improved by 72%." That specificity changes everything.

Under NICE guidelines, medication monitoring should include assessment of symptom change and functional impact. A qEEG comparison provides exactly this — at the neurological level rather than the subjective level. It doesn't replace clinical judgement. It informs it.

Who should consider a medication comparison scan

A medication comparison scan is particularly valuable if you find yourself in any of these situations:

• You've just started medication and want objective confirmation that it's having a neurological effect, rather than relying solely on subjective impression during the early weeks when placebo effects are strongest.
• You're considering a dose change and want to show your prescriber what the current dose is actually doing at a brain level before adjusting blindly.
• You're unsure if your medication is still working — perhaps you suspect tolerance has developed, or external factors have changed and you can't tell whether the medication is still contributing.
• You're comparing two medications — you've tried methylphenidate and switched to lisdexamfetamine (or vice versa) and want to see which produced a stronger neurological response. We can compare scans from different dates.
• Your child is on medication and can't articulate the effect — younger children often struggle to describe whether medication is "working." Brain data removes the need for self-report entirely.
• You're in a medication review and want evidence for your prescriber — objective data strengthens your position whether you want to continue, adjust, or discontinue treatment.

Taking the data to your prescriber

The medication comparison report is designed to be understood by clinicians. It includes raw data, z-scores, normative comparisons, attention task metrics, and a clinical interpretation section that contextualises the findings.

When presenting the report to your prescriber, focus on three things:

First, the theta/beta ratio change. Did it decrease with medication? By how much? Did it move closer to the normative range? This is the primary marker of medication-induced cortical arousal normalisation.

Second, the attention task metrics. Did accuracy improve? Did reaction time variability decrease? These are functional measures of the exact cognitive skills that medication should be enhancing — sustained attention, impulse control, and response consistency.

Third, the z-score context. Where does your medicated brain sit relative to the age-matched normative population? If your medicated theta/beta ratio is still 2+ standard deviations above the mean, there may be room for further optimisation. If it's within 1 standard deviation, the medication is achieving close to the expected neurological effect.

Our GP appointment guide includes specific language for presenting medication comparison data to prescribers. Most clinicians welcome objective data — it gives them something concrete to work with rather than navigating the inherent ambiguity of self-reported symptom change.

The future: personalised ADHD treatment

The field of precision psychiatry is moving towards treatment decisions guided by individual neurobiology rather than population-level averages. Research into EEG-guided treatment stratification — where your specific brain profile determines which treatment you receive — is advancing rapidly.

Studies at institutions including Research Institute Brainclinics have demonstrated that ADHD patients can be grouped into distinct neurophysiological subtypes — roughly 40% show the classic elevated theta pattern, while others show different profiles including excess beta, slowed alpha peak frequency, or atypical frontal asymmetry. Each subtype may respond differently to medication, neurofeedback, and behavioural intervention.

We're not there yet — clinical protocols for fully personalised treatment based on qEEG profiles are still being validated in large-scale trials. But the direction is clear. And in the meantime, the ability to see what your specific medication does to your specific brain — in objective, measurable terms — represents a significant step beyond the current standard of "how do you feel?"

Whether you're starting your first medication, questioning your current treatment, or advocating for your child's care, brain data gives you something that subjective reporting cannot: certainty. Not certainty about which medication is "best" — that's a clinical decision for your qualified prescriber. But certainty about what this medication is doing to this brain, right now, today.

And in a system where medication reviews are brief, waiting lists are long, and your prescriber is making decisions based on your imperfect recollection of the past month, that certainty matters enormously.

A note for parents

If your child has been prescribed ADHD medication, the medication comparison scan removes one of the most stressful aspects of the process: trying to determine whether the medication is working based on a child who may not be able to tell you.

Young children lack the metacognitive vocabulary to describe changes in their attention or impulse control. Teenagers may be resistant to acknowledging the medication helps, or conversely may attribute improvements to the medication when other factors have changed. Teachers observe your child in one context. You observe them in another. Your prescriber sees them for 15 minutes every few months. Everyone has a different piece of the picture, and nobody has the full picture.

Brain data cuts through all of this. A theta/beta ratio that drops from 2.6 to 1.1 with medication isn't a matter of interpretation. Attention accuracy that improves from 71% to 94% isn't subjective. These are measured, objective facts that you can present at the next medication review alongside the clinical observations — giving your prescriber the most complete picture possible.

Our parent's guide to ADHD covers the broader context of managing your child's ADHD journey, from the initial brain screening through to school support via EHCP evidence and GCSE exam access arrangements.

"My son couldn't tell us if the Concerta was helping. He'd shrug and say 'dunno.' The medication scan showed his theta/beta dropped from 2.6 to 1.1 and his attention accuracy went from 71% to 94%. That's not 'dunno' — that's transformative. We showed the report to his paediatrician and they were genuinely impressed."

Frequently asked questions